Spyre Therapeutics, Inc. (SYRE) Form 424B5 — Oct 5, 2026
Spyre Therapeutics filed a preliminary prospectus supplement for a marketed offering of common stock off its S-3 shelf, with Jefferies, TD Cowen, Leerink Partners, and Stifel as joint book-runners and LifeSci Capital as passive bookrunner. Pricing, share count, and expected proceeds were not yet disclosed as of the filing date. The last reported sale price was $93.19 on October 2, 2026, and the company had approximately $1.1 billion in cash and investments as of June 30, 2026, expected to fund operations into the second half of 2029.
Key figures
- Cash Position
- $1.1 billion (cash, cash equivalents and marketable securities as of June 30, 2026)
- Shares Outstanding
- 101905933
- Cash runway
- into the second half of 2029
- Last sale price date
- 2026-10-02
- Atm capacity remaining
- approximately $451.6 million under Sales Agreement
- Last reported sale price
- 93.19
- Net tangible book value per share
- 12.5
- Atm shares sold since june 30 2026
- 527502
- Pro forma net tangible book value per share
- 10.81
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.